<DOC>
	<DOCNO>NCT02184767</DOCNO>
	<brief_summary>This study ass pharmacokinetics loxapine use plasma concentration data obtain 48 hour administration study drug</brief_summary>
	<brief_title>Study Assess Safety Pharmacokinetics ADASUVE® Doses 2.5 , 5 , 10 mg Children Adolescents ( 10 Through 17 Years Age ) With Any Condition Warranting Chronic Use Antipsychotic Medication</brief_title>
	<detailed_description />
	<mesh_term>Loxapine</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Inclusion 1 . Written inform consent obtain patient 's parent legal guardian write assent obtain patient . 2 . The patient boy girl 10 17 year age . 3 . The patient within 2.5 97.5 percentile body mass index ( BMI ) basis age sex within follow weight range , appropriate : boy : 27 kg 127 kg less girl : 27 kg 111 kg less 4 . The patient document history schizophrenia , bipolar disorder , autism , condition use antipsychotic medication ( eg , risperidone , olanzapine , aripirazole , haloperidol , etc . ) warrant and/or administer . Note : Patients currently receive treatment condition must stable regimen ( dose frequency ) minimum 28 day administration ADASUVE . 5 . The patient good general health determine complete medical history ( include psychiatric respiratory ) , clinical laboratory test ( include hematology , serum chemistry , urinalysis ) , physical examination , body weight , 12lead ECG , spirometry , vital sign measurement ( blood pressure [ systolic diastolic ] , heart rate , body temperature , respiratory rate ) , pulse oximetry , chest auscultation , neurologic examination , suicidality assessment , concomitant medication usage inquiry . 6 . Female patient postmenarche sexually active must negative pregnancy test result , must exclusively sex partner use acceptable method contraception , must agree continue use method duration study 30 day discontinuation ADASUVE . Acceptable method contraception include abstinence intrauterine device ( know failure rate le 1 % per year ) . 7 . The patient negative alcohol test urine drug screen ( UDS ) result . A positive UDS result appropriate medical explanation ( eg , prescribed amphetamine ) may permit consultation medical monitor . Note : The UDS also detect presence tetrahydrocannabinol ( THC ) . A positive result THC may permit discussion sponsor result low consistent ( eg , positive predose assessment ) . If patient test negative THC screening , result must remain negative checkin patient eligible study participation . 8 . The patient parent/legal guardian must willing able comply study restriction remain investigational center require duration visit . Exclusion 1 . The patient clinically significant uncontrolled medical condition ( treat untreated ) condition specify inclusion criterion d. 2 . The patient current diagnosis history asthma , chronic obstructive pulmonary disease ( COPD ) , bronchiolitis , chronic bronchitis , emphysema , lung disease associate bronchospasm . 3 . The patient acute respiratory sign symptom ( eg , wheeze ) 4 . The patient currently know history follow : cardiovascular disease ( include , limited , myocardial infarction ischemic heart disease , heart failure , conduction abnormality ) cerebrovascular disease condition predispose hypotension ( include , limited , dehydration , hypovolemia , treatment antihypertensive medication drug affect blood pressure reduce heart rate ) seizure disorder except history infantile febrile seizures 5 . The patient pregnant lactating . 6 . The patient febrile . 7 . The patient disease condition , investigator 's medical monitor 's opinion , would present undue risk patient , may confound interpretation study result . 8 . The patient take follow drug , substance , food : investigational drug within 30 day 5 halflives ( whichever longer ) administration ADASUVE , case new chemical entity , 3 month 5 halflives ( whichever longer ) administration ADASUVE current use medication treat airway disease asthma COPD loxapine amoxapine within last 30 day 21 unit alcohol per week within past 2 year history alcohol , narcotic , substance abuse dependence define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR , American Psychiatric Association 2000 ) . Note : A unit alcohol equal 1 ounce hard liquor , 5 ounce wine , 8 ounce beer . clinically significant excessive consumption coffee , tea , and/or caffeinecontaining beverage food ( ie , 600 mg caffeine per day , 12ounce caffeinecontaining soda , 30 ounce chocolate , 5 cup coffee per day ) , combination beverage food within 2 week dose ADASUVE nicotinecontaining product ( include limit cigarette , cigar , chew dip tobacco ) within 12 month administration ADASUVE use topical oral nicotine preparation smoke cessation within past 3 month administration ADASUVE 9 . The patient know sensitivity idiosyncratic reaction loxapine amoxapine , compound present study formulation , metabolite , related compound . 10 . The patient history clinically significant cutaneous drug reaction , history clinically significant hypersensitivity reaction , include multiple allergy drug reaction . 11 . The patient known history contraindication anticholinergic ( eg , bowel obstruction , urinary retention , acute glaucoma ) . 12 . The patient procedure disorder may interfere drug absorption , distribution , metabolism , excretion ( include gastrointestinal surgery ; history appendectomy allow ) . 13 . The patient receive donated blood blood product ( eg , plasma platelet ) 3 month administration ADASUVE make 2 blood ( ≥ 450 mL ) blood product donation within 12 month administration ADASUVE , plan donate study within 3 month completion study . 14 . The patient 1 clinical laboratory test value outside range specify , clinically significant laboratory abnormality , determine investigator medical monitor : hemoglobin value le 11.0 g/dL twice upper limit normal range ( ULN ) total bilirubin value ULN 15 . With exception condition specify inclusion criterion , patient , within 4 week administration ADASUVE , clinically significant illness , within 1 week administration ADASUVE , acute illness , screen day administration ADASUVE , symptom clinically significant acute illness . 16 . The patient positive test result hepatitis B surface antigen ( HBsAg ) antibodies hepatitis C virus , know positive human immunodeficiency virus ( HIV ) history . 17 . The patient unable tolerate direct venipuncture . 18 . The patient blood pressure outside range 90 140 mm Hg ( systolic ) 50 90 mm Hg ( diastolic ) . Note : Only 2 rechecks permissible study eligibility purpose . 19 . The patient , rest 5 minute , oxygen saturation le 95 % . Note : Only 2 rechecks permissible study eligibility purpose . 20 . The patient evidence clinically significant ECG abnormality . 21 . The patient force expiratory volume 1 second ( FEV1 ) less 80 % predict value spirometry . 22 . The patient unlikely comply study protocol , unsuitable reason , judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>